DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2MO AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2MO AGO
Home/Compounds/Retatrutide
GLP-1 agonistRx required

Retatrutide

Also known as: LY3437943 · Triple G

Triple agonist (GIP/GLP-1/glucagon) in Phase 3 trials showing up to 24% weight loss.

B
Grade B
Human observational studies
Human studies25
PubMed citations30
Typical dose500 mcg – 12 mg
Routesubcutaneous
Regulatory (US)Rx required
Last verified2 months ago
TL;DR · 30-second summary
  • Up to 24.2% weight loss at 12mg dose in Phase 2
  • Superior to tirzepatide in early comparisons
  • Significant improvements in metabolic parameters
  • Phase 3 trials ongoing (2024-2025)

Mechanism of action

First triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Glucagon component may enhance fat oxidation and energy expenditure.

Evidence summary

25
Human studies
30
PubMed citations
25
Clinical trials
B
Evidence grade

Phase 2 trials showed unprecedented 24% weight loss at highest doses. Currently in Phase 3 trials for obesity and diabetes.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Dose range
500 mcg – 12 mg

Investigational. Phase 2 used 1-12mg weekly with dose escalation.

Administration routes
subcutaneous

Side effects & safety

Reported side effects
NauseaDiarrheaVomitingConstipationSimilar GI profile to GLP-1s
Contraindications
  • Not yet established - investigational

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Investigational - Phase 3 clinical trials

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/17/2026

Clinical trials

NCT07035093A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back PainRecruiting · Phase 3 · Obesity · n=586NCT07357415A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind TrialRecruiting · Phase 3 · Obesity · n=600NCT07232719A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled TrialActive Not Recruiting · Phase 3 · Obesity · n=250NCT07165028A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver OutcomesRecruiting · Phase 3 · Metabolic Dysfunction-Associated Steatotic Liver Disease · n=4500NCT06662383A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have ObesityActive Not Recruiting · Phase 3 · Obesity · n=800NCT06260722A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)Active Not Recruiting · Phase 3 · Diabetes Mellitus, Type 2 · n=1250NCT05929079A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled TrialActive Not Recruiting · Phase 3 · Type 2 Diabetes · n=1000NCT06383390A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney DiseaseActive Not Recruiting · Phase 3 · Atherosclerotic Cardiovascular Disease (ASCVD) · n=10000NCT07467447A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related ComorbiditiesRecruiting · Phase 2 · Obesity · n=300NCT06354660A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)Completed · Phase 3 · Diabetes Type 2 · n=537NCT06859268A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With ObesityActive Not Recruiting · Phase 3 · Obesity · n=643NCT06982859A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusRecruiting · Phase 1 · Diabetes Mellitus · n=95

Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 41054801Son JW, le Roux CW et al. · Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.Endocrine reviews (2026)HumanPMID 40094000Marathe SJ, Grey EW et al. · Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.npj metabolic health and disease (2026)PMID 41785010Panou T, Gouveri E et al. · Retatrutide in type 2 diabetes mellitus and obesity: an overview.Expert review of clinical pharmacology (2026)HumanPMID 39761578Moiz A, Filion KB et al. · Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.Annals of internal medicine (2025)HumanPMID 40699363Windram M, Lovelock DF et al. · Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.Psychopharmacology (2025)HumanPMID 40022548Madsbad S, Holst JJ · The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.Expert opinion on investigational drugs (2025)HumanPMID 40865172Rubio-Herrera MA, Mera-Carreiro S · Weight management treatment in obesity.Medicina clinica (2025)HumanPMID 40916752Kanu C, Boye KS et al. · Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.Diabetes, obesity & metabolism (2025)HumanPMID 40604322Caruso I, Cignarelli A et al. · Incretin-based therapies for the treatment of obesity-related diseases.npj metabolic health and disease (2025)PMID 41090431Giblin K, Kaplan LM et al. · Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.Diabetes, obesity & metabolism (2025)HumanPMID 38302593Melson E, Ashraf U et al. · What is the pipeline for future medications for obesity?International journal of obesity (2005) (2025)HumanPMID 39952695Kokkorakis M, Chakhtoura M et al. · Emerging pharmacotherapies for obesity: A systematic review.Pharmacological reviews (2025)HumanPMID 40563436Katsi V, Koutsopoulos G et al. · Retatrutide-A Game Changer in Obesity Pharmacotherapy.Biomolecules (2025)HumanPMID 39318607Pasqualotto E, Ferreira ROM et al. · Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.Metabolism open (2024)PMID 38843460Drucker DJ · Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.Diabetes care (2024)HumanPMID 38511400Hong SH, Choi KM · Gut hormones and appetite regulation.Current opinion in endocrinology, diabetes, and obesity (2024)HumanPMID 39481534Stefanakis K, Kokkorakis M et al. · The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.Metabolism: clinical and experimental (2024)HumanPMID 39305981Xie Z, Zheng G et al. · Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.Metabolism: clinical and experimental (2024)HumanPMID 38681750Ciardullo S, Muraca E et al. · Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.Gastroenterology report (2024)HumanPMID 39096466Himmerich H, Bentley J et al. · Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases.CNS drugs (2024)Human

Showing 20 of 30 papers. View all on PubMed →